ImClone, Merck KGaA deal

The companies extended their 1990 agreement to develop BEC-2, an anti-idiotypic vaccine for small cell lung carcinoma and malignant melanoma. IMCL will receive up to $11.7 million in license fees and quarterly milestone payments. Merck, which receives the marketing rights to the vaccine for all therapeutic indications outside of North America, also will pay for 60 percent of the development cost in the U.S. and Europe, and 100 percent of development costs in all other territories. IMCL will manufacture the product and receive royalties. ...